eligibility_summary
Eligible: pathologic gastric adenocarcinoma, clinical stage II–IVa (≥T3 and/or node+, no distant metastasis), received 2–4 cycles of 5‑FU+platinum neoadjuvant therapy ± trastuzumab or anti‑PD‑L1, then D2 radical gastrectomy, pre‑treatment contrast CT and HE biopsy images available, complete clinical data and targeted/immunotherapy marker expression. Exclude: other tumor history, poor‑quality imaging, unavailable molecular data, or interrupted neoadjuvant therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational study validating an AI radiopathomics system to predict response (TRG) to neoadjuvant therapy in locally advanced gastric adenocarcinoma. Interventions received: 1) 5‑FU + platinum chemotherapy (5‑FU = antimetabolite/pyrimidine analog, platinum = DNA crosslinker). 2) 5‑FU + platinum + trastuzumab (HER2‑targeted monoclonal antibody). 3) 5‑FU + platinum + anti‑PD‑1/PD‑L1 (immune checkpoint inhibitor monoclonal antibodies). Mechanisms: 5‑FU inhibits thymidylate synthase, disrupting DNA/RNA synthesis, platinum forms intra/interstrand DNA crosslinks, inducing apoptosis, trastuzumab blocks HER2/ErbB2 signaling and mediates ADCC, PD‑1/PD‑L1 blockade restores cytotoxic T‑cell activity. Targets/pathways: proliferating tumor cells (DNA synthesis/replication), HER2‑positive tumor cells (HER2→PI3K/AKT/MAPK), and immune checkpoints on T cells (PD‑1) and tumor/immune cells (PD‑L1).